It is great to see more unicorns in health tech AI. OpenEvidence is now valued at more than $3.5B...

It is great to see more unicorns in health tech AI. OpenEvidence is now valued at more than $3.5B after a $210M Series B backed by top-tier investors, including Sequoia Capital, Kleiner Perkins, GV (Google Ventures) Ventures, Coatue, among others. Impressive momentum, especially given their Series A was just completed in February.

The platform integrates directly into EHRs, aiming to offer physicians rapid, evidence-based answers powered by LLMs trained on medical literature. Yes, another "co-pilot," but one that's hopefully actually working.

GenAI is clearly starting to move beyond the pilot phase into daily practice. It's also encouraging to see funding dedicated explicitly to paid content partnerships. Perhaps we're finally moving past the era of scraping everything for free.

And it doesn't look like we're at the end of the AI hype cycle in health tech venture investment just yet.

Update (May 2026): since this post, OpenEvidence leaving Europe has shifted the story. The company withdrew from the EU and UK citing EU AI Act uncertainty, making the geography of clinical AI access officially American.

https://lnkd.in/eUGkWEQV